Yves Joseph Ribeill
Chief Executive Officer at Ribogenics, Inc.
Net worth: 44 583 $ as of 2024-03-30
Network origin in Yves Joseph Ribeill first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 30 | |
Ogeda SA
 Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.
12
| Subsidiary | Pharmaceuticals: Major | 12 |
Aventis Pharma SARL
 Aventis Pharma SARL Pharmaceuticals: MajorHealth Technology Founded in 1982, Aventis Pharma SARL is a French pharmaceutical company that manufactures pharmaceuticals. Part of Sanofi, the private company is based in Antony, France.
7
| Subsidiary | Pharmaceuticals: Major | 7 |
Ribogenics, Inc.
 Ribogenics, Inc. BiotechnologyHealth Technology Ribogenics, Inc. is a biotechnology company. The private company is based in Philadelphia, PA. The CEO of the company is Yves Joseph Ribeill.
3
| Private Company | Biotechnology | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Yves Joseph Ribeill via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ONCOTELIC THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| Thomas Jefferson University | College/University | Doctorate Degree | |
| SOLVAY SA | Chemicals: Specialty | General Counsel Compliance Officer | |
| CHIMERIX, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| TIGENIX NV | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
| University of Virginia | College/University | Corporate Officer/Principal Doctorate Degree | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree Graduate Degree | |
Rhone Poulenc Rorer
 Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | Chemicals: Specialty | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal General Counsel Corporate Officer/Principal | |
| The University of Southampton | College/University | Graduate Degree Undergraduate Degree | |
| University of London | College/University | Doctorate Degree Doctorate Degree | |
| University of British Columbia | College/University | Doctorate Degree Doctorate Degree | |
| INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
CropDesign NV
 CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director/Board Member | |
| VITAE PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| ENDOCYTE, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Stiefel Laboratories, Inc.
 Stiefel Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Stiefel Laboratories, Inc. engages in the manufacture of pharmaceutical products. It offers prescription and non-prescription dermatological and skin care products. The firm research, innovate and develop skin care treatments to health care professionals, patients and consumers. The company was founded in 1847 and is headquartered in Research Triangle Park, NC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| Université Libre de Bruxelles | College/University | Graduate Degree Corporate Officer/Principal Doctorate Degree | |
| École des Hautes Études Commerciales de Paris | College/University | Undergraduate Degree Undergraduate Degree | |
| Aventis Pharma AG | Director of Finance/CFO Corporate Officer/Principal | ||
Sanofi Pasteur
 Sanofi Pasteur BiotechnologyHealth Technology Sanofi Pasteur SA develops, manufactures and supplies vaccines. It provides vaccines for bacterial and viral diseases, including diphtheria, typhoid fever, and poliomyelitis. The company was founded in 1990 and is headquartered in Lyon, France. | Biotechnology | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| Université Catholique de Louvain | College/University | Doctorate Degree Graduate Degree Doctorate Degree | |
Vesalius Biocapital Partners SARL
 Vesalius Biocapital Partners SARL Investment ManagersFinance Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg. | Investment Managers | Private Equity Investor Private Equity Investor | |
| VOLUNTIS S.A. | Packaged Software | Director/Board Member | |
Apitope Technology (Bristol) Ltd.
 Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Miscellaneous Commercial Services | Director/Board Member | |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member | |
| Tranzyme Pharma, Inc. (Canada) | Corporate Officer/Principal Corporate Officer/Principal | ||
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| AQ Invest BV | Corporate Officer/Principal | ||
Themis Bioscience GmbH
 Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Vesalius Biocapital II Partners SARL | Founder | ||
| The University of North Carolina at Charlotte | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Solvay Business School of Economics & Management | College/University | Undergraduate Degree | |
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Biotechnology | Director/Board Member Director/Board Member | |
| ABIVAX | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
Novadip Biosciences SA
 Novadip Biosciences SA BiotechnologyHealth Technology Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Bio-Sourcing SA
 Bio-Sourcing SA BiotechnologyHealth Technology Bio-Sourcing SA develops and markets biological drugs for veterinary use. The firm focuses on farm animal health and companion animal health. The company was founded by Bertrand Mérot in June 2011 and is headquartered in Liege, Belgium. | Biotechnology | Director/Board Member | |
| ACTICOR BIOTECH SAS | Biotechnology | Director/Board Member | |
PharmaFluidics NV
 PharmaFluidics NV Electronic Equipment/InstrumentsElectronic Technology Pharmafluidics NV develops micro chip liquid chromatography cartridges for analysis of complex biological samples. The company was founded by Wim De Malsche, Joeri Denayer, Gert Desme and Paul Godelieve Jacobs in 2010 and is headquartered in Ghent, Belgium. | Electronic Equipment/Instruments | Chairman | |
Ncardia SA
 Ncardia SA Miscellaneous Commercial ServicesCommercial Services Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
Newton Biocapital Partners SRL
 Newton Biocapital Partners SRL Investment ManagersFinance Newton Biocapital Partners SPRL is an Independent Venture Capital firm founded in 2017 by Alain Parthoens. Newton Biocapital Partners SPRL is headquartered in Woluwe-Saint-Pierre. | Investment Managers | Founder | |
| AQ Partners SRL | Corporate Officer/Principal | ||
Epics Therapeutics SA
 Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | Miscellaneous Commercial Services | Founder Founder Chairman | |
Cellaïon SA
 Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
| A Q Invest SRL | Corporate Officer/Principal |
Statistics
International
| Belgium | 18 |
| United States | 15 |
| France | 9 |
| United Kingdom | 4 |
| Canada | 3 |
Sectoral
| Health Technology | 23 |
| Consumer Services | 13 |
| Commercial Services | 5 |
| Process Industries | 3 |
| Finance | 3 |
Operational
| Director/Board Member | 282 |
| Corporate Officer/Principal | 102 |
| Independent Dir/Board Member | 73 |
| Chairman | 51 |
| Undergraduate Degree | 31 |
Most connected contacts
| Insiders | |
|---|---|
| Jean-Paul Prieels | 32 |
| Alain Parthoens | 29 |
| Clarence Machado | 29 |
| Edward Penhoet | 29 |
| Mounia Chaoui-Roulleau | 27 |
| Ann Hanham | 26 |
| Steven Gilman | 25 |
| Patrick J. Langlois | 23 |
| Pamela Kirby | 22 |
| Laurent Arthaud | 21 |
| Jean-Jacques Bertrand | 21 |
| Michel Allé | 20 |
| Marco Taglietti | 16 |
| Jean-Yves Nothias | 16 |
| Marie Paule Richard | 15 |
- Stock Market
- Insiders
- Yves Joseph Ribeill
- Company connections
